Exelixis Inc(EXEL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low51.77
Day High53.70
Open:52.72
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Analysts Conflicted on These Healthcare Names: TScan Therapeutics (TCRX), Exelixis (EXEL) and AbbVie (ABBV)
Tipranks
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Kiora Pharmaceuticals (KPRX) and MAIA Biotechnology, Inc. (MAIA)
Tipranks
Exelixis Shareholders Approve Equity Plan and Board Slate
Motley Fool
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
MarketBeat
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near
MarketBeat.com
Tipranks
Exelixis Earnings Call Highlights Strong Cabo Momentum
Motley Fool
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal
Tipranks
Exelixis Advances Zanzalintinib Into Phase 2 Meningioma Trial, Signaling Pipeline Expansion
Motley Fool
Prediction: This Stock Could Double By 2031
Tipranks
Guggenheim Remains a Hold on Exelixis (EXEL)
Tipranks
Exelixis Earnings Call Highlights Growth And ZANZA Risks
Tipranks
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Contineum Therapeutics, Inc. Class A (CTNM) and Exelixis (EXEL)
Tipranks
Exelixis (EXEL) Gets a Hold from Wells Fargo
Tipranks
Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Henry Schein (HSIC) and Exelixis (EXEL)
Tipranks
Exelixis Posts Strong Q1 Results, Expands Share Buybacks
Motley Fool
Exelixis (EXEL) Q1 2026 Earnings Transcript
Tipranks
Exelixis and Merck Advance Key Phase 3 Kidney Cancer Trial, Setting Up a New Catalyst for EXEL
Tipranks
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Community Health (CYH)
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks

Profile

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.